Related Experiment Video
Updated: Sep 30, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Identification of Gαi3 as a promising target for osteosarcoma treatment
Zheng-Jun Bian1,2, Hua-Jian Shan1, Yun-Rong Zhu3
1Department of Orthopedics, Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Abstract:
Sustained activation of multiple receptor tyrosine kinases (RTKs) simultaneously is vital for tumorigenesis and progression of osteosarcoma (OS). Gαi proteins recruitment to various RTKs mediates downstream oncogenic signaling activation. The expression, functions and underlying mechanisms of Gαi3 in human OS were examined. Expression of Gαi3 is robustly elevated in human OS tissues and is correlated with a poor overall survival. In patient-derived primary OS cells and immortalized lines (MG63 and U2OS), Gαi3 depletion, by shRNA and CRISPR/Cas9 strategies, robustly suppressed cell viability, proliferation and migration, while provoking G1-S arrest and apoptosis activation. Conversely, Gαi3 overexpressing ectopically can accelerate proliferation and migration of OS cells. In OS cells, Gαi3 immunoprecipitated with VEGFR2, FGFR, PGDFR and EGFR, mediating downstream cascade transduction. Akt-mTOR activation in primary OS cells was potently inhibited by Gαi3 shRNA, knockout or dominant negative mutation, but augmented after Gαi3 overexpression. In vivo studies showed that Gαi3 shRNA AAV (adeno-associated viruses) intratumoral injection largely inhibited the growth of subcutaneous xenografts of primary OS cells. Moreover, the growth of the Gαi3-knockout primary OS xenografts was much slower than that of OS xenografts with empty vector. In Gαi3-depleted OS xenografts tissues, Gαi3 downregulation and Akt-mTOR inactivation were detected. Taken together, overexpressed Gαi3 mediates RTK-Akt signaling to drive OS progression.
Insights
G protein alpha i3 (Gαi3) drives osteosarcoma (OS) progression by activating receptor tyrosine kinase (RTK) signaling. Inhibiting Gαi3 suppressed tumor growth and survival, highlighting its potential as a therapeutic target in OS.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Osteosarcoma (OS) progression relies on sustained activation of multiple receptor tyrosine kinases (RTKs).
- G protein alpha i (Gαi) proteins mediate oncogenic signaling downstream of RTKs.
- The specific role of Gαi3 in human OS requires elucidation.
Purpose of the Study:
- To investigate the expression, function, and mechanisms of Gαi3 in human osteosarcoma.
- To determine the correlation between Gαi3 expression and patient survival.
- To assess the therapeutic potential of targeting Gαi3 in OS.
Main Methods:
- Analysis of Gαi3 expression in human OS tissues and cell lines (MG63, U2OS).
- Gαi3 depletion using shRNA and CRISPR/Cas9 gene editing.
- Assessment of cell viability, proliferation, migration, cell cycle, and apoptosis.
- Immunoprecipitation assays to identify RTK-Gαi3 interactions.
- In vivo studies using Gαi3-depleted xenograft models (AAV-mediated delivery).
Main Results:
- Gαi3 expression is significantly elevated in OS tissues and correlates with poor survival.
- Gαi3 depletion suppressed OS cell viability, proliferation, migration, induced G1-S arrest, and apoptosis.
- Gαi3 interacts with VEGFR2, FGFR, PDGFR, and EGFR, activating the Akt-mTOR pathway.
- In vivo, Gαi3 inhibition via intratumoral AAV injection significantly reduced xenograft growth.
Conclusions:
- Overexpressed Gαi3 is a key driver of osteosarcoma progression.
- Gαi3 mediates RTK-Akt signaling, promoting tumor growth and survival.
- Gαi3 represents a promising therapeutic target for osteosarcoma treatment.

